In today’s U.S. employment landscape, even well-trained biotech professionals with PhDs and specialized skill sets are having a hard time finding jobs. But for visa holders under H1B, the battle appears even more acutely defined.
A number of applicants say that as soon as employers become aware that visa sponsorship is required, the dialogue tapers off—or dies. Even when skills and experience match precisely, employers balk, invoking cost, timelines, or legal ambiguity.
Also Read – Indian Americans Top U.S. Income – But Feel Stuck
It’s not simply visas. The biotech employment market itself is experiencing a downturn. Following years of bullish funding and growth throughout the pandemic, the industry is now shrinking. Layoffs are routine, and hiring freezes have become standard at mid-cap and large firms.
For international workers, the risk is greater. Green card holders or citizens don’t face this same-time crunch between employment opportunities—and fewer businesses want to work through the paperwork these days.
Also Read – US Visa Blunder Ruins J-1 Student’s Career
Some business voices indicate that attitudes may turn more positive as funding cycles even out and the election-year clouds lift. But today, corporations are wary, and H1B resumes tend to get overlooked—regardless of candidate qualification.
This produces a maddening paradox: the ability is present, the demand is genuine, but the door is half-closed for those who lack permanent status.
